SCHEMBL2270236

SCHEMBL2270236

CN(C)c1ccc(-c2ccc(C(=O)O)c(NC(=O)c3ccccc3)c2)cc1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACLY P53396 3/20 0.61
MEN1 O00255 2/20 0.56
PKM P14618 2/20 0.56
KMT2A Q03164 2/20 0.56
MAPT P10636 1/20 0.56
GRIK1 P39086 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
DHODH Q02127 1/20 0.56
KCNK3 O14649 1/20 0.56
HDAC1 Q13547 5/20 0.55
HDAC2 Q92769 7/20 0.55
HDAC3 O15379 2/20 0.53
SUCNR1 Q9BXA5 1/20 0.52
SNCA P37840 1/20 0.52
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
SERPINE1 P05121 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2275453 0.87 ACLY (0.76) ACLYMEN1PKMKMT2AMAPT
SCHEMBL4563581 0.85 ACLY (0.65) ACLYMEN1PKMKMT2AMAPT
SCHEMBL2273186 0.85 ACLY (0.68) ACLYMEN1PKMKMT2AMAPT
SCHEMBL2276006 0.85 HDAC1 (0.48) ACLYMEN1PKMKMT2AMAPT
SCHEMBL2270222 0.84 DHODH (0.77) ACLYMEN1PKMKMT2AMAPT
SCHEMBL2269341 0.84 HDAC2 (0.71) ACLYMEN1PKMKMT2AMAPT
SCHEMBL1317676 0.84 ACLY (0.54) ACLYDHODHHDAC1HDAC2
SCHEMBL2274974 0.83 ACLY (0.67) ACLYMEN1PKMKMT2AMAPT
SCHEMBL2269268 0.83 ACLY (0.67) ACLYMEN1PKMKMT2AMAPT
SCHEMBL27696829 0.83 HDAC1 (0.47) ACLYTDP1KCNK3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ACLY 653/4885MEN1 3105/4885PKM 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.